Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The company's products are used in various applications that range from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, it offers contract manufacturing and formulation services. Teligent, Inc. sells its products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was founded in 1977 and is based in Buena, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TLGT
CUSIPN/A
Phone856-697-1441
Debt
Debt-to-Equity Ratio3.31
Current Ratio2.77
Quick Ratio1.79
Price-To-Earnings
Trailing P/E Ratio-18.21
Forward P/E Ratio-26.62
P/E GrowthN/A
Sales & Book Value
Annual Sales$67.25 million
Price / Sales2.75
Cash Flow$0.0730 per share
Price / Cash47.39
Book Value$0.84 per share
Price / Book4.12
Profitability
EPS (Most Recent Fiscal Year)($0.19)
Net Income$-15,190,000.00
Net Margins-62.19%
Return on Equity-50.85%
Return on Assets-11.81%
Miscellaneous
Employees183
Outstanding Shares53,540,000
Market Cap$183.10 million
Teligent (NASDAQ:TLGT) Frequently Asked Questions
What is Teligent's stock symbol?
Teligent trades on the NASDAQ under the ticker symbol "TLGT."
How were Teligent's earnings last quarter?
Teligent Inc (NASDAQ:TLGT) announced its quarterly earnings results on Wednesday, August, 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.02) by $0.18. The firm had revenue of $16.75 million for the quarter, compared to analyst estimates of $16.06 million. Teligent had a negative return on equity of 50.85% and a negative net margin of 62.19%. View Teligent's Earnings History.
When is Teligent's next earnings date?
What price target have analysts set for TLGT?
1 brokers have issued twelve-month target prices for Teligent's shares. Their predictions range from $4.00 to $4.00. On average, they expect Teligent's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 15.6% from the stock's current price. View Analyst Price Targets for Teligent.
What is the consensus analysts' recommendation for Teligent?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teligent in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Teligent.
Who are some of Teligent's key competitors?
Some companies that are related to Teligent include ProQR Therapeutics (PRQR), Dynavax Technologies (DVAX), Flexion Therapeutics (FLXN), Epizyme (EPZM), Insys Therapeutics (INSY), ANI Pharmaceuticals (ANIP), Vectura Group (VEGPF), CymaBay Therapeutics (CBAY), AC Immune (ACIU), Assembly Biosciences (ASMB), GlycoMimetics (GLYC), Obseva (OBSV), Kura Oncology (KURA), ChemoCentryx (CCXI) and Dova Pharmaceuticals (DOVA).
Who are Teligent's key executives?
Teligent's management team includes the folowing people:
- Mr. Jason Grenfell-Gardner M.B.A., M.B.A, Pres, CEO & Director (Age 43)
- Mr. Stephen Richardson, Chief Scientific Officer (Age 52)
- Mr. Martin Wilson, Gen. Counsel (Age 41)
- Mr. Damian Finio, Corp. Sec. & CFO (Age 48)
- Ms. Nadya Lawrence, Sr. VP of Technical Services (Age 49)
Who are Teligent's major shareholders?
Teligent's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sanders Morris Harris LLC (2.72%) and Sanders Morris Harris LLC (0.01%). Company insiders that own Teligent stock include Carole Ben-Maimon, Jason Grenfell-Gardner, Jenniffer Collins, Stephen Richardson and Steven H Koehler. View Institutional Ownership Trends for Teligent.
Which institutional investors are selling Teligent stock?
How do I buy shares of Teligent?
Shares of TLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teligent's stock price today?
One share of TLGT stock can currently be purchased for approximately $3.46.
How big of a company is Teligent?
Teligent has a market capitalization of $183.10 million and generates $67.25 million in revenue each year. The company earns $-15,190,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Teligent employs 183 workers across the globe.
What is Teligent's official website?
How can I contact Teligent?
Teligent's mailing address is 105 LINCOLN AVENUE, BUENA NJ, 08310. The company can be reached via phone at 856-697-1441 or via email at [email protected]
MarketBeat Community Rating for Teligent (NASDAQ TLGT)
MarketBeat's community ratings are surveys of what our community members think about Teligent and other stocks. Vote "Outperform" if you believe TLGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLGT will underperform the S&P 500 over the long term. You may vote once every thirty days.
